Compare FRD & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRD | DERM |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 135.3M |
| IPO Year | 1995 | 2021 |
| Metric | FRD | DERM |
|---|---|---|
| Price | $20.64 | $5.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 22.4K | ★ 238.8K |
| Earning Date | 06-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ 34.72 |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $121,157,278.00 | $61,858,000.00 |
| Revenue This Year | N/A | $39.72 |
| Revenue Next Year | N/A | $63.24 |
| P/E Ratio | $14.02 | ★ N/A |
| Revenue Growth | ★ 55.82 | 10.20 |
| 52 Week Low | $14.52 | $4.31 |
| 52 Week High | $24.37 | $9.56 |
| Indicator | FRD | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 57.15 |
| Support Level | $20.54 | $4.84 |
| Resistance Level | $22.76 | $7.66 |
| Average True Range (ATR) | 1.01 | 0.37 |
| MACD | -0.15 | 0.12 |
| Stochastic Oscillator | 33.39 | 60.11 |
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.